Deliver Consulting Limited | Back to main site

Program Overview

China and Asia over the decades has been playing an increasingly important role in the context of clinical research activities due to the significant scientific investment by multinational companies as well as rapidly booming China domestic R&D programs. In past few years, the China regulatory agency has also issued several regulations and initiatives to accelerate the review and approval and improve the quality of new drugs and medical devices. With the joining of ICH in 2017, the government is continuing to improve the regulatory standards and systems to promote innovation, enhance the R&D ecosystem. However, the drug development is fraught with all kinds of challenges which needs innovation, efficiency and collaboration. In return, the Clinical Development and Innovation Forum will gather leaders and scientists across pharma, biotech and academia for discussions and cases studies on the major topics including: Robust Clinical and Regulatory Strategy, Next Generation Clinical Trials, Oncology and Immuno-Oncology Drug Development, CNS New Drug Development, Clinical Biomarkers and Companion Diagnostics, Cellular Immunotherapy and Gene Therapy Development, Data Science and Digital Innovation, China Domestic R&D Innovation, Innovative Clinical Design and Patient Strategies etc. towards the Efficient and GCP-compliant Drug Development in the era of Precision Medicine.


2022 Speaker Committee

  • Hongjun Yang

    Founder and Co-Director, The Committee of Precision Medicine
    Chinese Society of Biotechnology


  • Simon Li

    Chief Medical Officer
    Evive Biotech


  • Junyuan Wang

    AnHeart Therapeutics


  • Gary Tong

    Co-Founder and CMO
    NeuroFront Therapeutics


  • Hua Gong

    Senior Vice President, Translational Medicine and Clinical Biomarkers
    Zai Lab


  • Yukun Wang

    Head of Translational Medicine Oncology China
    Bayer Healthcare


  • Helen Jiang

    Chief Medical Officer
    Zhejiang YST Co.,ltd



Program Key Discussions

  • Clinical and Regulatory Strategy, Next Generation Clinical Trials
  • Oncology and Immuno-Oncology Drug Development
  • Cellular Immunotherapy, Gene Therapy, Oncolytic Virus Immunotherapy Development
  • CNS Diseases and AutoImmune Diseases Novel Therapey Development
  • Bioanalysis, Biomarkers, Companion Diagnostics and Translational Medicine
  • Biotherapeutics, Bispecific Antibodies and ADC Development
  • China Domestic New Drug Development and Translational Research
  • Innovative Clinical Design and Biostatistics
  • Early and Exploratory Drug Development Strategies
  • Real-world Research, Digital innovation and Virtual Trials
  • AI and Big Data in Drug Development

Who would Attend

Approx. 700 senior R&D, Clinical and Translational, Medical and Regulatory executives and scientists are expected to attend the Clinical Development and Innovation Forum 2022. The participants will mainly come from the Pharma/Biotech, Academia, Investigational Sites, Regulatory Agencies, CROs, Central Labs, Technology and Service providers with the main responsibilities including:

- Corporate Executives and Head of R&D
- Clinical and Regulatory Strategy
- Medical Sciences and Affairs
- Biomarkers, Companion Diagnostics and Translational Medicine
- Clinical Innovation and Strategy
- Clinical Data Sciences and Biostatistics
- Clinical Operation and Quality Management
- Clinical Procurement and Sourcing
- Principal Investigators